Hello, I wanted to provide an update on my husband's progression and, hopefully, some of you may have some knowledge to share or have a similar profile. His psa has risen from <0.04 since RP for Stage 3b to 0.06 in 9/23. A recheck a week later showed a rise to 0.1. This was followed by a drop to <.04 a week later followed by another <.04 the following week. We thought we were in the clear, but were shocked to see his psa rose to .16 a month later (11/9), A PSMA Pet Scan revealed small radiotracer activity in the lower abdominal/pelvic area lymph nodes of periaortal caval, aortic caval, common illac and retrocaval node. The largest SUV max was 10.4 in the retrocaval node although the node is not enlarged. This is considered by Yale to be stage M1A. A repeat psa on 12/5/23 revealed his psa had risen to .273 (so a definite biochemical occurence).My husband's surgical oncologist at Yale immediately referred him to a Medical Oncologist who started him on Casodex followed by Lupron two weeks later. This was immediately followed by Zytiga with 5 mg prednisone. He recommends this ADT treatment until it fails in approximately three years. We consulted with two radiation oncologists (one in Hartford and one at Yale who specialize in Salvage RT for biochemical recurrence of prostate cancer. Both said it would be feasible to radiate the pelvis and extend the field to the affected nodes using 70 gy in 39 treatments. He is set to be CT mapped in February with a start date for radiation at the end of February. They want to proceed with curative intent, although we have been cautioned by our Medical Oncologist that this may bring many side effects without the benefit of a cure. If we can stall or delay progression with the hopes of my husband having a durable remission or even the potential to take a break from ADT, then we deemed it worth it. We are visiting Memorial Sloan Kettering tomorrow to get expert opinions on our treatment plan and their take on the SBRT radiation (Stampede trial) . I am also wondering if radiation is not the most optimal treatment, then why not add a 6 week cycle of Docetaxel to the mix of ADT.? This would be considered triplet therapy (Stampede trial). His current medical oncologist at Yale is against chemo at this time because he is considered low burden, early metastatic. Yet, I need to ascertain if the chemo would be more effective on the hormone specific cancer rather than waiting for it to mutate to MCRPC. That is another question, I will be asking Sloan Kettering about. Finally, his inflammation markers are very high, and these came up at the same time as his psa began to rise. He has very high RA factors, high CRP and granulocytes. As our son has Sarcoidosis in remission, I will be inquiring if these autoimmune findings could cause a false positive psma uptake on the scan. With his rising psa, it is doubtful. We will meet with Memorial Sloan Kettering tomorrow followed by a meeting with his oncologist at Yale next week. I will keep you posted.
Stephanie